FGFR2 isoforms support epithelial-stromal interactions in thyroid cancer progression

Miao Guo1, Wei Liu, Stefano Serra

  • 1The Ontario Cancer Institute, Department of Medicine, University Health Network, Toronto, Ontario, Canada.

Cancer Research
|February 21, 2012
PubMed

Insights

Fibroblast growth factor (FGF) receptor variants FGFR2-IIIb and FGFR2-IIIc show tumor-suppressive effects in thyroid cancer cells but promote fibroblast growth, highlighting context-dependent functions.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Fibroblast growth factor (FGF) receptor (FGFR) expression is frequently dysregulated in human thyroid cancer.
  • Alternate splicing of FGFR2 generates distinct isoforms, FGFR2-IIIb and FGFR2-IIIc, with varying extracellular structures.

Purpose of the Study:

  • To investigate the functional roles of FGFR2-IIIb and FGFR2-IIIc isoforms in modulating thyroid cancer cell behavior.
  • To understand the impact of these FGFR isoforms on tumor growth, invasion, and metastasis in vivo and in vitro.
  • To explore the influence of cellular context on the growth-promoting or suppressing activities of FGFR isoforms.

Main Methods:

  • Enforced expression of FGFR2-IIIb or FGFR2-IIIc in thyroid epithelial cancer cells.
  • Assessment of gene expression changes (fibronectin, MAGE-A3, MMP9, p21) and Rb dephosphorylation.
  • In vitro invasion assays and in vivo tumor growth and metastasis studies using xenograft models.
  • Co-implantation experiments with epithelial and fibroblast cells expressing specific FGFR isoforms.

Main Results:

  • Expression of FGFR2-IIIb or FGFR2-IIIc in thyroid cancer cells reduced fibronectin, MAGE-A3, and MMP9, while increasing p21 and Rb dephosphorylation.
  • Both isoforms exhibited tumor-suppressive properties, diminishing invasion in vitro and reducing tumor growth and metastasis in vivo.
  • In contrast, these isoforms stimulated fibroblast cell growth.
  • Co-expression of FGFR2-IIIb in epithelial cells and FGFR2-IIIc in fibroblasts enhanced tumor progression, indicating context-dependent effects.

Conclusions:

  • Cellular context is crucial in determining the growth-modulating properties of FGF receptor isoforms.
  • Alternative splicing of FGFR2 generates heteroisoforms with distinct epithelial-stromal effects critical for FGF-mediated growth promotion in thyroid cancer.
  • These findings underscore the complex roles of FGFR isoforms in thyroid cancer progression and suggest potential therapeutic targets.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...